Mid-To-Late-Stage Investor Longitude Capital Closes $385M Second Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
A history of strong returns from the firm, which backs both private and public health care companies, compelled existing investors to return for a new fund. Still, Longitude retained a placement agent to find new limited partners as an “insurance policy.”
You may also be interested in...
As Some VCs Refill, Others Are Running Out Of Gas
Life science VCs are posting strong across-the-board returns, allowing some firms to raise new funds larger than their prior vehicles. Still, the contraction that began nearly five years ago continues to thwart other firms’ efforts to press on through hard times.
As Some VCs Refill, Others Are Running Out Of Gas
Life science VCs are posting strong across-the-board returns, allowing some firms to raise new funds larger than their prior vehicles. Still, the contraction that began nearly five years ago is still thwarting other firms’ efforts to press on through hard times.
Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M
Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.